Claims for Patent: 10,682,426

Summary for Patent: 10,682,426

Title:	Rabies vaccine
Abstract:	The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of Rabies virus or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of Rabies virus or a fragment, variant or derivative thereof. Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of Rabies virus infections. The present invention further describes a method of treatment or prophylaxis of rabies using the mRNA sequence.
Inventor(s):	Schnee; Margit (Constance, DE), Kramps; Thomas (Tubingen, DE), Stitz; Lothar (Rottenburg, DE), Petsch; Benjamin (Tubingen, DE)
Assignee:	CureVac AG (Tubingen, DE)
Application Number:	15/048,356
Patent Claims:	1. A method of treatment or prophylaxis of rabies virus infections comprising the steps: a) providing an mRNA having a sequence comprising a coding region encoding glycoprotein G (RAV-G) of Rabies virus, wherein the G/C content of the coding region is increased compared with the G/C content of the coding region of the wild type mRNA, and wherein the coded amino acid sequence of said GC-enriched mRNA is not being modified compared with the coded amino acid sequence of the wild type mRNA, and wherein: (i) the mRNA comprises a sequence at least 95% identical to SEQ ID No: 24; or (ii) wherein the mRNA further comprises a 5'-UTR element which comprises a nucleic acid sequence which is derived from the 5'UTR of a TOP gene; b) applying or administering the mRNA to a tissue or an organism; c) optionally administering rabies immune globulin. 2. The method of claim 1, wherein the coding region encodes the full-length protein of glycoprotein G (RAV-G) of Rabies virus. 3. The method of claim 1, wherein the glycoprotein G (RAV-G) is from a Rabies vaccine strain. 4. The method of claim 1, wherein the mRNA further comprises a) a 5'-CAP structure, b) a poly(A) sequence, c) and optionally a poly (C) sequence. 5. The method of claim 4, wherein the poly(A) sequence comprises a sequence of about 25 to about 400 adenosine nucleotides. 6. The method of claim 1, wherein the mRNA further comprises at least one histone stem-loop. 7. The method of claim 1, wherein the mRNA further comprises a 3'-UTR element. 8. The method of claim 7, wherein the 3'UTR element comprises a nucleic acid sequence which is derived from a 3'UTR of a gene providing a stable mRNA or from a homolog. 9. The method of claim 8, wherein the 3'UTR element comprises a nucleic acid sequence derived from a 3'UTR of a gene selected from the group consisting of an albumin gene, an .alpha.-globin gene, a .beta.-globin gene, a tyrosine hydroxylase gene, a lipoxygenase gene, and a collagen alpha gene. 10. The method of claim 9, wherein the 3'-UTR element comprises a nucleic acid sequence derived from a 3'UTR of .alpha.-globin gene. 11. The method of claim 7, wherein the at least one 3'UTR element comprises a nucleic acid sequence which is derived from the 3'UTR of a vertebrate albumin gene. 12. The method of claim 11, wherein the 3'UTR element is derived from a nucleic acid sequence according to SEQ ID NO. 18. 13. The method of claim 1, wherein the mRNA comprises, in 5'- to 3'-direction: a) a 5'-CAP structure; b) a coding region encoding at least one of glycoprotein G (RAV-G) of Rabies virus; c) a 3'-UTR element comprising or consisting of a nucleic acid sequence which is derived from an alpha globin gene or an albumin gene; d) a poly(A) sequence; e) a poly(C) sequence; and f) a histone-stem-loop. 14. The method of claim 13, wherein the mRNA comprises the RNA sequence of SEQ ID No. 24. 15. The method of claim 1, wherein the mRNA further comprises a 5'-UTR element which comprises a nucleic acid sequence which is derived from the 5'UTR of a TOP gene. 16. The method of claim 15, wherein the 5'UTR element comprises a nucleic acid sequence which is derived from a 5'UTR of a TOP gene encoding a ribosomal protein. 17. The method of claim 16, wherein the 5'UTR element comprises a nucleic acid sequence which is derived from a 5'UTR of a TOP gene encoding a ribosomal Large protein (RPL).

Details for Patent 10,682,426

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bavarian Nordic A/s	RABAVERT	rabies vaccine	For Injection	103334	October 20, 1997	10,682,426	2033-08-21
Sanofi Pasteur Sa	IMOVAX RABIES	rabies vaccine	For Injection	103931	February 04, 2000	10,682,426	2033-08-21
Octapharma Pharmazeutika Produktionsges.m.b.h.	OCTAGAM	immune globulin intravenous (human)	Injection	125062	May 21, 2004	10,682,426	2033-08-21
Octapharma Pharmazeutika Produktionsges.m.b.h.	OCTAGAM	immune globulin intravenous (human)	Injection	125062	March 26, 2007	10,682,426	2033-08-21
Octapharma Pharmazeutika Produktionsges.m.b.h.	OCTAGAM	immune globulin intravenous (human)	Injection	125062	July 11, 2014	10,682,426	2033-08-21